10-K: SeaStar Medical Reports Revenue Growth Amidst Going Concern Doubts

SeaStar Medical Holding Corporation's latest 10-K filing reveals increased revenue from its pediatric SCD therapy but highlights substantial doubt about its ability to continue as a going concern due to ongoing losses and capital needs.

Summary

• SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life.
• The company's Selective Cytopheretic Device (SCD) is designed to neutralize over-active immune cells and stop the cytokine storm that causes destructive hyperinflammation.
• FDA approval was received on February 21, 2024, under a Humanitarian Device Exemption (HDE) for its pediatric SCD therapy, QUELIMMUNE, making it the only FDA-approved product for pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy.
• The first commercial pediatric SCD (QUELIMMUNE) was shipped in July 2024, and as of December 31, 2025, the company had 10 active commercial hospital customers.
• The company is conducting a pivotal clinical trial, NEUTRALIZE-AKI, to assess the safety and efficacy of SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy (CRRT), with 178 patients enrolled as of March 13, 2026.
• SCD therapy has been awarded six Breakthrough Device Designations (BDD) by the FDA for multiple therapeutic indications, including adult AKI, Cardiorenal Syndrome (CRS), hepatorenal syndrome, end-stage renal disease (ESRD), and systemic inflammatory response during cardiac surgery.
• Clinical and preclinical studies have demonstrated that SCD therapy can modulate proinflammatory cells, with data from over 150 pediatric and adult AKI patients on CRRT showing a 50% reduction in mortality rates, and no dialysis required for 60-day survivors.
• Net revenue increased to $1.2 million for the year ended December 31, 2025, compared to $0.1 million for the year ended December 31, 2024.
• The net loss for the year ended December 31, 2025, was $12.2 million, an improvement from a net loss of $24.8 million in 2024.
• As of December 31, 2025, the company had an accumulated deficit of $151.7 million and cash of $12.0 million.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern for the twelve-month period following the issuance date of the financial statements.
• Ongoing class action and derivative lawsuits allege material misstatements and omissions regarding FDA approval prospects and deficiencies in internal financial controls, leading to a restatement of previously issued financial statements.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, early-commercialization stage company with promising technology and regulatory milestones, but significant financial instability and a clear going concern warning. While revenue growth and reduced losses are positive, the fundamental capital needs and legal challenges overshadow these gains.

Positives

• Received FDA approval on February 21, 2024, for its pediatric SCD therapy (QUELIMMUNE) under a Humanitarian Device Exemption (HDE).
• QUELIMMUNE is the only FDA-approved product for pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy.
• Shipped its first commercial pediatric SCD (QUELIMMUNE) in July 2024 and expanded to 10 active commercial hospital customers by December 31, 2025.
• SCD therapy has been awarded six Breakthrough Device Designations (BDD) by the FDA, which can expedite clinical development and regulatory review for various indications.
• Early commercial data from 21 pediatric patients in the SAVE Surveillance Registry showed no device-related safety events, 76% survival through 60 days, and 71% survival through 90 days, validating a projected 50% reduction in mortality.
• The FDA approved a reduction in the mandatory enrollment size of the SAVE Surveillance Registry from 300 to 50 patients in December 2025, with the 50th patient enrolled on March 4, 2026, indicating positive safety data.
• Net revenue increased significantly to $1.2 million in 2025 from $0.1 million in 2024, an 814% increase.
• Net loss decreased to $12.2 million in 2025 from $24.8 million in 2024, a 51% reduction, driven by increased revenue and decreased operating expenses.
• Achieved positive working capital of $9.8 million as of December 31, 2025, compared to a negative working capital of $3.0 million in 2024.
• Successfully raised approximately $24.5 million in gross proceeds through various equity offerings and agreements in 2025.
• Regained compliance with Nasdaq's minimum bid price requirement on January 20, 2026.

Negatives

• Incurred significant net losses since inception, with an accumulated deficit of $151.7 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months due to recurring operating losses and negative cash flows from operations.
• Current cash of $12.0 million as of December 31, 2025, is insufficient to fund operations for the next 12 months.
• The company has a limited operating history, making it difficult to accurately forecast future results of operations.
• Revenue is currently dependent on a single product (QUELIMMUNE), and HDE restrictions limit the number of units that can be sold annually, thus limiting potential revenue.
• Heavy reliance on additional equity and debt financings, with no assurance of securing capital on favorable terms or at all, which could lead to substantial dilution for shareholders or curtailment of development efforts.
• Ongoing class action and derivative lawsuits allege material misstatements and deficiencies in internal controls, posing significant legal and financial risks and diverting management's attention.
• Relies on a single supplier (Fresenius Medical Care North America) for critical SCD cartridges and blood tubing sets, creating supply chain disruption risks.
• Limited manufacturers/suppliers for regional citrate anticoagulation (RCA) and calcium replacement IV solutions, which are essential for SCD use, posing further supply chain risks.
• The company's Common Stock is under a Mandatory Panel Monitor by Nasdaq until July 1, 2026, with a risk of delisting if compliance with listing standards is not maintained.
• Past identification of material weaknesses in internal controls over financial reporting.

Risks

• Incurred significant losses since inception and anticipates continued significant losses for the foreseeable future.
• Has not generated substantial revenue to date and may never be profitable.
• May suffer from lack of availability of additional funds.
• There is substantial doubt about the ability to continue as a going concern.
• In the event of a restructuring or reorganization under applicable law, the company will be subject to associated risks and uncertainties.
• Has a limited operating history, making it difficult to forecast future results of operations.
• Ability to use net operating losses (NOLs) to offset future taxable income may be subject to certain limitations (e.g., Section 382 of the Code).
• May become a defendant in stockholder derivative, class-action, and other litigation.
• May face challenges in obtaining additional FDA approvals to market products in the United States or abroad.
• The United States could change tariff, trade, or tax provisions related to the manufacturing and sales of products.
• May not be able to manage growth effectively, straining resources and delaying business objectives.
• Changing priorities within the U.S. government resulting in the loss of government grant funding could adversely impact future growth plans.
• Will initially depend on revenue generated from a single product and, in the foreseeable future, a limited number of products.
• May fail to comply with extensive regulations of United States and foreign regulatory agencies.
• Delays in successfully completing planned clinical trials could jeopardize the ability to obtain regulatory approval.
• Delays, interruptions, or cessation of production by third-party suppliers of important materials or delays in qualifying new materials may prevent or delay manufacturing.
• Difficulties in manufacturing SCD could have an adverse effect upon revenue and expenses.
• SCD technology may become obsolete due to new scientific or technological developments.
• Faces intense competition in the medical device industry.
• If products, or their malfunction, cause or contribute to a death or serious injury, the company will be subject to medical device reporting regulations, potentially leading to corrective actions or enforcement.
• Outsources many operational and development activities, for which it may not have full control.
• Lack of third-party coverage and reimbursement for devices could delay or limit their adoption.
• Adverse changes in reimbursement policies and procedures by payors may impact the ability to market and sell products.
• May be subject to enforcement action if engaging in improper marketing or promotion of products.
• Exposed to product liability risks, and clinical and preclinical liability risks, which could place a substantial financial burden should litigation be pursued.
• United States legislative or FDA regulatory reforms may make it more difficult and costly to obtain regulatory approval and to manufacture, market, and distribute products.
• Subject to stringent and changing privacy laws, regulations, and standards.
• Business operations will be adversely affected if security measures, or those maintained on its behalf, are compromised, limited, or fail (cybersecurity risks).
• Depends on key personnel, and inability to attract and retain qualified personnel could impede business objectives.
• Products may in the future be subject to product recalls.
• Forecasted operating and financial results rely upon assumptions and analyses that may prove incorrect.
• Estimates of market opportunity, industry projections, and forecasts of market growth may prove to be inaccurate.
• Conflicts, military actions, terrorist attacks, political events, public health crises, changes in regulatory regimes, and general instability could adversely affect the business.
• Relies upon exclusively licensed patent rights from third parties which are subject to termination or expiration.
• If unable to obtain and maintain sufficient patent protection for products, the ability to commercialize them successfully may be adversely affected.
• May not be able to obtain protection under the Hatch-Waxman Act and similar non-United States legislation for extending the term of patents.
• Could become involved in intellectual property litigation that could be costly, require payment of damages, prevent sales, or reduce margins.
• Issued patents covering one or more products could be found invalid or unenforceable if challenged.
• If unable to protect the confidentiality of trade secrets, the value of technology could be adversely and materially affected.
• The United States government may exercise certain rights with regard to inventions, or licensors' inventions, developed using federal government funding.
• Changes to patent law in the United States and other jurisdictions could diminish the value of patents.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment, and other requirements.
• May obtain only limited geographical protection with respect to certain patent rights.
• Does not have long-term experience operating as a United States public company.
• Common Stock may be delisted from Nasdaq if compliance with continued listing requirements is not maintained.
• Inability to develop and maintain an effective system of internal controls over financial reporting could impact accurate and timely financial reporting.
• The sale of Common Stock in at-the-market offerings, through its standby equity purchase agreement, or similar arrangements may cause substantial dilution to existing shareholders.
• May redeem unexpired warrants prior to their exercise at a time that is disadvantageous to holders, making warrants worthless.
• The trading price of Common Stock has been volatile and is likely to be volatile in the future.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Future sales, or the possibility of future sales, of a substantial number of shares of Common Stock could adversely affect the price and dilute stockholders.
• Has not paid cash dividends in the past and does not expect to pay dividends in the future.
• Is an 'emerging growth company' and intends to continue to take advantage of reduced disclosure and governance requirements.

Future Outlook

The company anticipates reporting topline clinical trial results for its NEUTRALIZE-AKI study and submitting a Pre-market Approval (PMA) application in 2027. Subject to additional funding, it plans to increase research and development expenses to continue developing its SCD and a next-generation SCD. General and administrative expenses are also expected to rise due to new hires, travel, and infrastructure investments. Future product sales are highly dependent on securing coverage and reimbursement from government and private payors. The company intends to pursue business development opportunities, including partnerships and outbound licensing, and to scale production with manufacturing partners. Revenue generation will continue to focus on QUELIMMUNE sales, with fluctuations expected quarter-to-quarter. Additional funding will be required to sustain operations beyond the next 12 months.

Management Comments

• "Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions, or expectations."
• "We believe our technology has the potential to overcome limitations in existing anti-inflammatory treatments and address the challenge of selectively targeting activated neutrophils and monocytes."
• "We believe our SCD therapy has the potential to transform the treatment of acute organ failure in the intensive care unit (ICU) and to improve organ function in patients with chronic kidney disease, certain cardiovascular diseases, and other serious inflammatory diseases."
• "We believe these data are on track to validate a 50% reduction in loss of life compared to historical data."
• "We anticipate reporting topline clinical trial results and, assuming a successful trial outcome, submission of a Pre-market Approval ('PMA') application in 2027."
• "We believe that our SCD therapy is readily applicable for use in other indications as well, which will increase the addressable market for our SCD therapy, but will also require additional clinical studies and FDA approval."
• "We believe that our SCD is able to compete effectively in the market and we are not aware of any similar device that has completed regulatory approval in any country for the treatment of adults or children with acute kidney injury requiring continuous renal replacement therapy."
• "We believe that this raises substantial doubt about our ability to continue as a going concern."
• "Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2025."

Industry Context

StockSavvy.ai notes that SeaStar Medical operates in the highly competitive medical device industry, specifically targeting hyperinflammatory conditions and organ failure, a market with substantial clinical need and economic burden (AKI hospital costs estimated between $5.4 billion and $20 billion per year in the U.S.). The company's focus on a "first-in-class" Selective Cytopheretic Device (SCD) positions it uniquely against existing suboptimal treatments that are either immunosuppressive or target specific cytokines. The receipt of six FDA Breakthrough Device Designations underscores the innovative potential of its technology, aligning with a broader industry trend towards expedited pathways for novel, high-impact medical solutions. The growing demand for ICU renal replacement therapy, with a global market estimated at $986 million in 2019, provides a favorable backdrop for SeaStar Medical's SCD, which integrates into existing CRRT systems. The company's strategy to leverage medical education and pursue business development opportunities with major medical and pharmaceutical companies reflects a common approach in the biotech/medtech sector to gain market acceptance and scale, especially for novel therapies.

Comparison to Industry Standards

• The company's pediatric SCD therapy (QUELIMMUNE) is the only FDA-approved product for pediatric AKI due to sepsis or a septic condition requiring kidney replacement therapy, indicating a unique market position.
• Clinical data from over 150 pediatric and adult AKI patients on CRRT demonstrated a 50% reduction in mortality rates, which compares favorably to the standard of care therapy associated with a >50% 60-day mortality (Tumlin JA, et al. Semin Dial. 2013).
• In the SCD-003 trial, the per-protocol cohort showed a 60-day mortality rate of 16% in the SCD-treated group compared to 41% in the control group, and a composite endpoint of mortality and/or dialysis dependency at day 60 of 16% vs. 58%, respectively, demonstrating significant clinical benefit over standard CRRT alone.
• Early commercial results from 21 pediatric patients in the SAVE Surveillance Registry showed 76% survival through 60 days and 71% through 90 days, validating a projected 50% reduction in loss of life compared to historical data.
• Health economic outcomes research (HEOR) projected QUELIMMUNE therapy to be cost-beneficial, lowering mortality and reducing hospital length of stay by 3 days in pediatric AKI patients requiring CKRT, with estimated savings of ~$40,000 per hospitalization after six days of QUELIMMUNE use. This positions the device as a cost-effective solution, a critical factor for hospital adoption compared to other high-cost, low-efficacy treatments.
• The company's SCD technology is described as "first-in-class" and "transformative, if not disruptive," suggesting it aims to set a new standard rather than incrementally improve existing therapies.

Corporate Governance

Legal Proceedings

• **Class Action Lawsuit (Wells v. SeaStar Medical Holding Corporation et al.)**: Filed July 5, 2024, in the U.S. District Court for Colorado by Forrest A K Wells, a purported stockholder. Alleges material misstatements/omissions regarding FDA approval timing and financial instrument recognition, leading to a restatement of consolidated financial statements. Claims under Section 10(b) and 20(a) of the Exchange Act against the company, CEO, and former CFO. Seeks compensatory damages. An amended complaint was filed March 4, 2025. Magistrate Judge O'Hara recommended dismissal with leave to amend on February 27, 2026. Lead Plaintiff objected on March 13, 2026, with Defendants expected to respond March 27, 2026.
• **Derivative Action Lawsuit (Lazo v. Schlorff et. al.)**: Filed December 13, 2024, in the U.S. District Court for Colorado by Jose Lazo, a purported stockholder. Factual allegations are substantially similar to the Class Action. Alleges CEO, former CFO, and certain current/former directors violated Section 14(a) of the Exchange Act, breached fiduciary duties, and were unjustly enriched by false/misleading statements about FDA approval prospects and deficiencies in internal financial controls leading to restatement. Claims under Section 10(b) and 21D of the Exchange Act against CEO and former CFO. Seeks damages, restitution, and injunctive relief concerning corporate governance and internal controls. Stayed on January 30, 2025, pending resolution of motion to dismiss in the Class Action.
• Former directors have threatened litigation for purported harm to the company and made demands regarding alleged contractual rights and agreements, which the company disputes.

Related Party Transactions

• The company co-owns patents with the University of Michigan (UOM) and holds an exclusive worldwide, royalty-bearing license from UOM for their interest in these patents.
• Agreed to pay UOM a 1% royalty on net sales and a one-time milestone payment of $0.1 million upon FDA approval (paid in 2024).
• Reimburses UOM for patent costs (approximately $0.1 million paid since January 2020).
• In October 2024, the license agreement was amended to eliminate 10% of any milestone payments/fees in exchange for extending the 1% royalty on net sales until the later of patent expiration or the 10-year anniversary of the first commercial sale.
• The UOM License Agreement limits UOM's liability and requires the company to indemnify UOM in connection with the use of the licensed technology.

Stakeholder Impact

• **Shareholders**: Face potential for significant dilution from ongoing equity financing, stock price volatility, risk of delisting from Nasdaq, and potential loss of investment due to going concern doubts and ongoing legal proceedings.
• **Employees**: Success depends on retaining key personnel and attracting qualified scientific, technical, and managerial staff in a competitive market. Equity incentives may be impacted by stock price performance.
• **Customers (Hospitals/Clinicians)**: Benefit from the only FDA-approved pediatric AKI device (QUELIMMUNE), offering a novel treatment option. However, the adoption process can be lengthy due to Institutional Review Board (IRB) requirements. Potential for new adult AKI treatment if ongoing trials are successful.
• **Suppliers**: The company's reliance on single-source suppliers for critical components (e.g., cartridges, blood tubing sets) and limited manufacturers for essential IV solutions creates supply chain risks that could impact product availability.
• **Creditors**: The substantial doubt about the company's ability to continue as a going concern raises concerns about its capacity to meet future debt obligations.
• **Regulatory Authorities (FDA)**: The company's operations are subject to extensive FDA regulations, with ongoing engagement for clinical trials, Breakthrough Device Designations, Humanitarian Device Exemption, and future Pre-market Approval applications. Compliance is critical for market access and continued operations.

Next Steps

• Continue to target top-tier pediatric medical facilities for adoption of QUELIMMUNE therapy in 2026.
• Evaluate additional clinical development opportunities in children, including for systemic inflammatory response in pediatric patients undergoing cardiac surgery.
• Continue enrollment and treatment of patients in the NEUTRALIZE-AKI pivotal clinical trial for adult AKI.
• Anticipate reporting topline clinical trial results for NEUTRALIZE-AKI and submitting a Pre-market Approval (PMA) application in 2027.
• Evaluate additional clinical development of SCD therapy in adults based on unmet clinical needs and market opportunity, leveraging BDD awards.
• Continue to explore the application of SCD therapy across a broad range of indications where proinflammatory activated neutrophils and monocytes contribute to disease progression or severity.
• Plan a pilot safety and efficacy study in 10 patients at UOM to evaluate the reduction in myocardial stunning events in hemodialysis patients.
• Dedicate resources to educate physicians, hospital clinicians, and other decision-makers on the role of neutrophils and monocytes and the therapeutic benefit of SCD therapy.
• Explore and pursue business development opportunities with major medical and pharmaceutical companies, including outbound licensing arrangements.
• Identify and secure various suppliers and manufacturing partners to scale production.
• Continue to negotiate with suppliers of raw materials to establish redundancies and alternative sources.
• Develop a comprehensive reimbursement strategy including CMS, private payors, and other key stakeholders.
• File the 2026 proxy statement on or before April 29, 2026.
• Defendants are expected to respond to the Lead Plaintiff's objection in the Class Action on March 27, 2026.
• The company will need to secure additional capital to continue operations beyond the next 12 months.

Key Dates

Recommendation

Despite some positive operational developments like increased revenue and reduced net loss, the company faces a "substantial doubt about its ability to continue as a going concern" for the next 12 months, as explicitly stated by management and the independent auditor. This fundamental financial instability, coupled with an accumulated deficit of $151.7 million and insufficient cash to fund operations, presents an extremely high risk profile. The ongoing class action and derivative lawsuits further compound these risks, potentially leading to significant legal costs and reputational damage. While the SCD technology shows promise and has received FDA approvals and designations, the company's precarious financial position and heavy reliance on highly dilutive equity financing make it a "strong sell" for seasoned investors, as the risk of significant capital loss far outweighs the speculative upside.

Keywords

SeaStar Medical, SCD, QUELIMMUNE, Acute Kidney Injury, Sepsis, CRRT, Breakthrough Device Designation, Humanitarian Device Exemption, Cardiorenal Syndrome, Hepatorenal Syndrome, End-Stage Renal Disease, Hyperinflammation, Cytokine Storm, Medical Device, Clinical Trials, FDA Approval, Biotechnology, Healthcare, Financial Reporting, Going Concern, Equity Financing, Nasdaq, SEC Filing, 10-K